Systemic Erythropoietin Injection in Patients Having Optic Atrophy
NCT ID: NCT04680143
Last Updated: 2021-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
10 participants
INTERVENTIONAL
2020-09-01
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Atropine on Pupil Size and Quality of Vision
NCT06071260
Low-dose Atropine for Myopia Control in Children
NCT03865160
Ocular Changes With Alpha-2 Receptor Agonist.
NCT05670015
Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia
NCT03381079
Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia
NCT05448989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Follow up after one month and three months by recording visual acuity and electro physiological studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic erythropoietin injections
The study included 10 patients diagnosed as post papilledemic optic atrophy
Systemic erythropoietin injection
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systemic erythropoietin injection
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Fahmy Doheim
Prinicipal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mai ElBahwash, PhD
Role: PRINCIPAL_INVESTIGATOR
Alexandria Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria Faculty of Medicine
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0304845
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.